ELCC 2016: Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
GENEVA, Switzerland, 14 April 2016 – Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.
ELCC 2016: Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
GENEVA, Switzerland, 14 April 2016 – The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small- cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 A second late-breaking abstract confirms the drug’s effectiveness in patients with the T790M mutation.
DENVER – Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors.
DENVER – Trained technician screeners with assisted computer-aided nodule detection or computer vision (CV) screening workstations can efficiently and accurately review and triage abnormal low-dose computed topography (LDCT) scans for radiologist review.
DENVER – A cross-sectional survey showed a quarter of patients with detected incidental pulmonary nodules experienced significant distress related to the nodule. Detailed clinician communication increased patient knowledge, relieved distress, and improved patient experience.
DENVER – Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer.